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 In two articles in this issue of  Kidney Inter-
national 1,2 (and two others to appear in a 
future issue), Matsushita and colleagues 
report associations between albuminuria 
or estimated glomerular fi ltration rate and 
all-cause mortality or cardiovascular mor-
tality. Th e studies were well conducted, 
the results are robust within and across 
studies, and the fi ndings should reinforce 
the importance of these two measures in 
risk profi ling for bedside decision making 
and for public-health screening programs. 
Th e major intrinsic limitation is the pres-
ence of substantial statistical heterogene-
ity without clinical explanation in the 
meta-analyses. Th is limitation is acknowl-
edged by the authors. Th e fi nding of het-
erogeneity implies that the overall result 
and level of statistical signifi cance will not 
hold for some sub-populations, because 
statistical hetero geneity means, by defi ni-
tion, that the underlying true eff ect varies 
and will sometimes be smaller than the 
mean estimate and fail to attain the same 
level of signifi cance. 
 A deeper concern about this hetero-
geneity relates to the validity of the infer-
ence itself. For validity, the fi xed-eff ects 
model requires the assumption that the 
constituent trial eff ects all estimate the 
same underlying true eff ect. By contrast, 
the random-eff ects model requires the 
assumption that the trial eff ects conform 
to a specifi ed distribution, and a  ‘ uni-
verse of trials ’ is postulated to defi ne its 
domain of inference. Users of this model 
claim inference to the universe of trials 
in patients with the condition of interest. 
Critics question the random-effects 
model on foundational grounds, as it is 
based on this abstruse, even inchoate, 
notion of a universe of trials. 3 Th e fi xed-
eff ects model, by contrast, has a more 
modest goal, claiming inference only to 
trials akin to those trials used in the 
analysis. This is the crux of the long-
standing fi xed-eff ects-versus-random-
eff ects debate. 
 Importantly, the fixed-effects model 
does not rely on heterogeneity testing 
except as a  post hoc check on the data. 
In fact, users of the fi xed-eff ects model 
caution against overreliance on heteroge-
neity testing in general, because such tests 
tend to be dominated by unstable contri-
butions from smaller studies, and because 
some heterogeneity of the size of the treat-
ment effect (though not usually of its 
direction) will almost certainly, in reality, 
be expected across trials regardless of het-
erogeneity measures. 4 If the clinical ques-
tion is well understood and entails little 
clinical heterogeneity, the fixed-effects 
model is justifi ed. 5 Otherwise, the applica-
tion of meta-analysis is not considered 
appropriate. 6 In essence, a judgment 
regarding clinical similarity is needed prior 
to the decision to use meta-analysis. 
 Avoidance of relying on heterogeneity 
testing, and a focus, instead, on under-
standing and minimizing clinical hetero-
geneity, have not occurred. Th e practice 
of using the fixed-effects model in the 
absence of heterogeneity and the random-
eff ects model in its presence has become 
widespread despite repeated advice 7 that 
statistical heterogeneity cannot simply be 
dealt with by defaulting to a random-
effects model. When major statistical 
heterogeneity is found, exploration is rec-
ommended to reveal the underlying clin-
ical factors responsible. When such factors 
are identified, the study question and 
inference can be redirected at a more 
clinically homogeneous group of popula-
tions. However, there is yet no agreed-on 
approach to how this should be done and 
how to protect this process from being 
data-driven. Finally, if no clinical explana-
tions for heterogeneity are found and the 
heterogeneity is major, meta-analysis 
should probably not be used at all. 
 In the studies by Matsushita and col-
leagues, 1,2 one is concerned that the extent 
of statistical heterogeneity refl ects excess 
clinical heterogeneity, which compromises 
validity. Th is holds whether the random-
eff ects or the fi xed-eff ects model is used. 
The issue is whether the analytic tool 
of meta-analysis is appropriate given 
the formulation of the study question. A 
case could be made for a more thorough 
exploration for clinical heterogeneity, 
for example, the use of clear outliers 
in the analyses. In their defense, the 
authors argue that the consistency of 
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the findings across diverse studies, 
diff ering populations, and diff erent anal-
yses indicates the robustness of the 
results, which, in the end, makes infer-
ence more convincing. One might not 
disagree with this argument, but it is not 
a statistically based argument, and it 
does not mitigate concern about the 
validity of the inference. 
 More broadly, what are the practical 
implications of these data? Individual 
practitioners and policy makers will have 
to weigh the uncertainty in the conclu-
sions against the uncertainty associated 
with alternatives at the patient or public-
health level. Th is presents a major chal-
lenge because incorporating risk-factor 
data into treatment decisions presupposes 
that treatments exist that, if applied early, 
ameliorate risk — that is, altering a 
risk factor translates into an improved 
outcome. However, this last proposition 
cannot be assumed without empirical evi-
dence, as the checkered history of surro-
gate validity clearly demonstrates. Th ere 
are numerous examples 8,9 of markers 
where epidemiology fails to correctly pre-
dict the outcome of an analysis of rand-
omized trials measuring both marker and 
outcome. A robust demonstration of the 
surrogate / outcome relationship in rand-
omized trials may result in surrogate 
 ‘ validation, ’ conditional on the drug class, 
populations, and outcomes studied. Th e 
commercial attraction is then new-drug 
approval based on measurement of only 
the surrogate, which can usually be 
accomplished with much smaller, shorter, 
and cheaper trials. However, in reality, 
approval decisions are complicated and 
nuanced, and what constitutes the  ‘ same 
drug class ’ may not be obvious. 
 A program of scientifi cally based deci-
sions to implement evidence from  risk-
factor and surrogate-marker data requires 
well-developed evidence from randomized 
trials measuring both surrogate and out-
come (not yet available in renal disease). 
It will also require comparison of evidence 
across diff erent conditions and interven-
tions. With observational data there are 
established approaches for these compar-
isons, including use of risk equations and 
population attributable risk. However, 
procedures have not yet been developed 
for comparing randomized-trial data on 
one surrogate and outcome with those on 
a diff erent surrogate and outcome. Th e 
recent Biomarker-Surrogacy Evaluation 
Schema (BSES) 10 ( Table 1 ) attempts to 
start a process of developing instruments 
to this end. Th e BSES proposes a common 
metric to quantify across medical condi-
tions the evidentiary strength of surrogate /
 outcome relationships in the overall 
management of patients. 
 As a contrast to renal disease, it is useful 
to explore a surrogate / outcome example 
with more data — stroke prevention with 
antihypertensive drugs. Early observa-
tional evidence strongly supported blood 
pressure as an important risk factor for 
stroke, and the seminal Oxford meta-
analysis 4 of interventional randomized 
trials measuring both blood pressure and 
vascular events showed a clear reduction 
in stroke, 42 % , for a 5-mm  Hg reduction 
in diastolic blood pressure. A fi xed-eff ects 
model was used, and no heterogeneity was 
found (  2 13   =  12.4,  P   =  not signifi cant). 
A recent meta-analysis 11 using a random-
eff ects model found similar stroke reduc-
tions for 5-mm  Hg diastolic blood pressure 
and 10-mm  Hg systolic blood pressure 
reductions but with substantial statistical 
heterogeneity (  2 24   =  55,  P   <  0.001), so 
this meta-analysis is not as convincing. 
 A recent approach, the  ‘ surrogate thresh-
old eff ect ’ (STE), may off er a better vehicle 
to compare across surrogates and across 
medical conditions. Th e STE 12 arises from 
a meta-regression of existing surrogate /
 outcome trials (and patient-level data if 
available). Th e STE is defi ned as that diff er-
ence between test and control surrogate 
change needed in a new trial measuring 
only the surrogate to impute, with 95 % con-
fi dence, an outcome benefi t. Th e STE is that 
 Table 1  |   The Biomarker-Surrogacy Evaluation Schema 2010 (ref.  10 ) (updated at 
2010 Joint Statistical Meetings, Vancouver, Canada) 
 Study design 
  •  0  Biological plausibility and lower-quality clinical studies 
  •  1  At least 2 high-quality prospective observational studies 
  •  2  At least 2 high-quality, adequately powered RCTs measuring  S and  T 
  •  3  At least 5 high-quality, adequately powered RCTs measuring  S and  T 
 Target outcome 
  •  0  Reversible disease-centered biomarker of harm 
  •  1  Irreversible disease-centered biomarker of harm 
  •  2  Patient-centered end point of reversible organ morbidity or burden-of-disease or clinical 
harm 
  •  3  Patient-centered clinical end point of irreversible severe organ morbidity or burden-of-
disease or severe irreversible clinical harm OR death 
 Statistical strength of biomarker for target 
  •  0  Poor 
  •  1  Fair:  R 2 trial   0.2 and STEP 
a   0.1 and  R 2 ind   0.2 
  •  2  Good:  R 2 trial   0.4 and STEP   0.2 and  R 
2 ind   0.4 
  •  3  Excellent:  R 2 trial   0.6 and STEP   0.3 and  R 
2 ind   0.6 (without data subdivision 
b ) 
 Generalizability of biomarker – target relationship: clinical evidence across diff erent risk populations and 
pharmacologic evidence across diff erent drug-class mechanisms 
  •  0  No clinical or pharmacologic evidence 
  •  1  Clinical or pharmacologic evidence 
  •  2  Clinical and pharmacologic evidence 
  •  3  Consistent clinical RCT and pharmacologic RCT evidence 
Abbreviations: ind, individual; RCT, randomized controlled trial; S, surrogate; T, true.
 The Biomarker-Surrogacy Evaluation Schema consists of four domains, each with hierarchical criteria. The overall 
summed score ranges from 0 to 12. The score is converted to a surrogate / outcome  ‘ level of evidence ’ with the most 
convincing, level 1, being a score 12 and the least convincing, level 5, a score 0, 1, or 2. Intermediate are level 2, 
scores 9 – 11; level 3, scores 6 – 8; and level 4, scores 3 – 5. 
 a STEP is defi ned as that proportion of the total range of the surrogate that is equal to or larger than the surrogate 
threshold eff ect (STE). 10 
 b Some analyses with few trials subdivide into centers to increase the number of data points. (Adapted with 
permission from Prof. Marissa Lassere.) 
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point on the graph of the meta-regression 
where the lower 95 % prediction band inter-
sects with the horizontal (no-eff ect) axis. 
An STE using negatively controlled trials 
has been demonstrated for low-density 
lipoprotein cholesterol and statin therapy 12 
and, more recently, for diastolic and systolic 
blood pressure and antihypertensive ther-
apy (KJ and M Lassere, unpublished data). 
 In summary, in comparison with stroke 
prevention, there is a shortage of trials 
demonstrating that treatment-associated 
diff erences in achieved levels of albuminu-
ria or estimated glomerular fi ltration rate 
translate into reductions in important 
outcomes. Without these, one cannot sub-
stantiate an argument for the use of albu-
minuria or estimated glomerular fi ltration 
rate as a surrogate in treatment decisions. 
Stevens  et al. , 13 in a recent review, suggest 
that a by-trial analysis of studies measur-
ing both proteinuria and renal outcomes 
is feasible with published data. Until such 
analyses are available, there will remain 
uncertainty surrounding treatment or 
policy recommendations based on these 
risk factors. 
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 PPAR-  transcriptional activity is 
required to combat doxorubicin-
induced podocyte injury in mice 
 Kiyoshi  Mori 1 ,  Masashi  Mukoyama 1 and  Kazuwa  Nakao 1 
 Immunosuppressants and inhibitors of the renin angiotensin system 
are major reagents to treat nephrotic syndrome, but their clinical 
effects are not necessarily satisfactory. Injection of doxorubicin in 
several strains of mice causes nephrotic syndrome – like disorder. 
Zhou  et al. report that PPAR-  expression is downregulated in 
murine doxorubicin nephropathy and a PPAR-  agonist, fenofibrate, 
partially ameliorates the disorder induced likely through stabilization 
of nephrin expression and suppression of apoptosis in podocytes, 
providing a new preventive strategy. 
 Kidney International (2011)  79, 1274 – 1276;  doi: 10.1038/ki.2011.36 
 Podocyte injury plays an important role in 
various proteinuric disorders. Because 
podocytes in adult humans and rodents 
have little proliferative activity, cellular 
stress in podocytes tends to accumulate, 
and podocyte loss cannot be recovered. 1 
Th erefore, protection of podocytes in renal 
disorders should be a major strategy to pre-
vent worsening of renal failure, especially 
in chronic disease, but drugs clinically avail-
able for that goal are not very eff ective. 
 Peroxisome proliferator-activated 
receptors (PPARs) possess various activi-
ties, including not only enhancement of 
fatty acid oxidization but also suppression 
of infl ammation, apoptosis, and fi brosis. 2 
Fenofi brate is a PPAR-  agonist widely 
used to treat hypertriglyceridemia 
patients, and its use may also be benefi cial 
for cardiovascular disorders. Animal 
studies have shown that treatment with 
PPAR-  ligand or transgenic overexpres-
sion of PPAR-  in proximal tubules can 
ameliorate the development of cisplatin-
induced or renal ischemia / reperfusion-
induced acute kidney injury and diabetic 
nephropathy. 3,4 
 Doxorubicin (adriamycin, or DOX) is 
an anthracycline class of chemotherapy 
reagent used to treat solid or  hematopoietic 
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